Verrica Pharmaceuticals Inc.
VRCA
$6.84
$0.6310.15%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 46.06% | 1,380.23% | 905.39% | 145.35% | -10.12% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 46.06% | 1,380.23% | 905.39% | 145.35% | -10.12% |
| Cost of Revenue | 74.53% | 118.68% | 16.69% | -39.39% | -55.29% |
| Gross Profit | -61.84% | 180.81% | 338.69% | 687.39% | 131.77% |
| SG&A Expenses | 12.90% | -17.83% | -41.53% | -46.42% | -45.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.39% | 3.14% | -32.80% | -45.09% | -48.41% |
| Operating Income | -19.50% | 38.68% | 107.86% | 109.93% | 56.29% |
| Income Before Tax | 0.62% | 50.17% | 98.80% | 101.19% | 52.08% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 0.62% | 50.17% | 98.80% | 101.19% | 52.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 0.62% | 50.17% | 98.80% | 101.19% | 52.08% |
| EBIT | -19.50% | 38.68% | 107.86% | 109.93% | 56.29% |
| EBITDA | -20.07% | 38.65% | 108.49% | 110.94% | 56.40% |
| EPS Basic | 55.76% | 76.22% | 99.41% | 100.58% | 76.51% |
| Normalized Basic EPS | 55.76% | 81.37% | 99.41% | 100.58% | 76.51% |
| EPS Diluted | 55.88% | 76.22% | 99.41% | 100.54% | 76.45% |
| Normalized Diluted EPS | 55.76% | 81.37% | 99.41% | 100.58% | 76.51% |
| Average Basic Shares Outstanding | 124.65% | 109.57% | 102.76% | 104.04% | 104.02% |
| Average Diluted Shares Outstanding | 124.65% | 109.57% | 102.76% | 104.09% | 104.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |